

Supplemental table: Overview of patients with a facial nerve palsy during follow-up and respective characteristics as well as reasons for exclusions of events from the main and sensitivity analysis.

No. of event	Pt-term of FNP	pt-terms of events that occurred up 2 weeks prior to FNP (explanation)	pt-terms of Events between >2 weeks and 3 months prior to FNP	Relevant baseline comorbidities*	Treatment exposure group	Time to event from baseline (in months)	Analysis	Reasons for exclusion from all analysis or from sensitivity analysis
1	Facial paralysis	None	None	None	Rituximab	70	Main analysis Sensitivity analysis	
2	Facial paralysis	None	None	None	Control	59	Main analysis Sensitivity analysis	
3	Facial paralysis	None	None	None	Etanercept	3	Main analysis Sensitivity analysis	
4	Facial paralysis	None	None	Hypertension	Control	22	Main analysis Sensitivity analysis	
5	Facial paralysis	None	None	Hypertension	Etanercept	27	Main analysis Sensitivity analysis	
6	Facial paralysis	None	None	Hypertension	Tocilizumab	5	Main analysis Sensitivity analysis	
7	Facial paralysis	Ulcerative keratitis	None	None	Control	59	Main analysis Sensitivity analysis	
8	Facial paresis	None	None	Hypertension	Etanercept	12	Main analysis Sensitivity analysis	
9	Facial paresis	None	None	None	Tocilizumab	83	Main analysis Sensitivity analysis	
10	Facial paresis	Cholangitis sclerosing, Crohn's disease	None	None	Etanercept, Rituximab	48	Main analysis Sensitivity analysis	
11	Facial paresis	Vertigo positional	None	Hypertension, Diabetes	Abatacept	36	Main analysis Sensitivity analysis	
12	Facial paresis	Rheumatoid arthritis (flare)	None	Hypertension, Diabetes, Ovarian cancer [#]	Abatacept, Baricitinib	16	Main analysis Sensitivity analysis	
13	Facial paralysis	Streptococcal infection	Mammoplasty	Hypertension	Tocilizumab	28	Main analysis	FNP after infectious disease
14	Facial paralysis	Tonsillitis, Mucocutaneous candidiasis	None	Hypertension	Rituximab	101	Main analysis	FNP after infectious disease
15	Facial paralysis	Abscess jaw,	None	Hypertension, Diabetes	Tocilizumab	22	Main analysis	FNP after dental treatment
16	Facial paresis	None	None	Hypertension, Basal cell carcinoma [§]	Abatacept	59	Main analysis	FNP after dental treatment
17	Facial paresis	Bronchitis bacterial	Renal function test abnormal	Hypertension	Rituximab	13	Main analysis	FNP after infectious disease
18	Facial paresis	Mastoiditis, Deafness neurosensory	None	None	Etanercept	85	Main analysis	FNP after infectious disease
19	Facial paresis	Headache	None	Sjogren's syndrome	Rituximab	1	Main analysis	Sjogren's syndrome
20	Facial paresis	Renal artery stenosis, Dysarthria, Arterial injury, Cerebral infarction	None	Hypertension	Etanercept	-	Exclusion from all analyses	FNP after stroke
21	Facial paralysis	Thalamic infarction, Catheter site infection, Norovirus test positive	None	Diabetes, Cerebrovascular event	Infliximab	-	Exclusion from all analyses	FNP after stroke
22	Facial paralysis	Encephalitis	None	Diabetes	Golimumab	-	Exclusion from all analyses	FNP after encephalitis

Abbreviations: FNP, facial nerve palsy.

*Comprises hypertension, diabetes, any malignancy and Sjogren syndrome.

§First diagnosis: 3.5 years before FNP. Malignancy was reported during follow-up observation of the patient.

#First diagnosis: 45 years before FNP.